Hoosiers Work for Health

05/28/2026

"If a charity organization collected billions of dollars with little evidence that needy people benefited, regulators and the public would quickly demand answers.
Yet many large hospital systems participating in the federal 340B Drug Pricing Program are quietly doing just that—extracting billions in drug discounts with scarce oversight and no obligation to prove vulnerable patients benefit."

-Sally Pipes, President, CEO, Thomas W. Smith Fellow in Health Care Policy at the Pacific Research Institute

When hospitals overcharge insurers for drugs they bought at deep 340B discounts, taxpayers, employers, and insured patients foot the bill.

05/26/2026

European experts are not speaking hypothetically. As director of the Austrian Economics Center and a member of Austria’s National Council, Barbara Kolm has direct experience with the European drug pricing systems some want the U.S. to adopt. Her warning about the risks to innovation and future cures should not be taken lightly.

Today, medical leaps that once took decades are now happening in months.

05/18/2026

For families managing serious or chronic conditions, copay assistance can mean the difference between getting treatment or going without it.

Indiana’s new patient-first laws help ensure those savings actually reach patients instead of being absorbed by insurance companies and pharmacy benefit managers. National Kidney Foundation of Indiana CEO Liz Ellis explains why these reforms matter for Hoosier families.

Indiana lawmakers have taken bold steps to put patients ahead of harmful insurance practices. Hoosier patients, not insurance giants, should start benefiting at the pharmacy counter.

05/14/2026

Programs designed to support rural healthcare should benefit rural communities, not large, urban hospital systems exploiting loopholes.

A new study examining Medicare “dual classification” adds to growing concerns about transparency and accountability in programs like 340B. In a new piece from the Goshen News, Indiana State Grange President Jason Smith weighs in on what’s at stake for rural Hoosiers.

Rural Hoosiers have a simple way of life. My neighbors and fellow Grange members prefer it that way, but that doesn’t mean they should have to sacrifice access to quality

05/11/2026

A federal judge's ruling on a North Dakota 340B law is shining a light on what has become one of healthcare’s biggest loopholes.

Hospitals acquire drugs at steep discounts and contract pharmacies profit while patients often see no savings at all.

The Wall Street Journal Editorial Board says policymakers can no longer ignore the problem.

A federal judge shows how this hospital ‘discount’ fleeces drug makers and patients.

05/08/2026

A safety net program should protect patients, not leave them drowning in medical debt.

A new analysis highlights concerns that some 340B hospitals continue aggressive debt collection practices despite receiving major federal drug discounts.

Patients deserve clarity on how 340B dollars are being used to help them.

NCL finds many 340B hospitals more aggressive on medical debt, raising patient protection concerns.

05/04/2026

Senator Todd Young recently sat down with the Making Medicine Podcast to discuss the growing risks of relying on China for critical biotech inputs, the urgent need for faster and more predictable FDA processes and the policies required to keep the United States competitive in a rapidly evolving global landscape.

From supply chain vulnerabilities to the rise of AI-driven drug development, this discussion highlights how innovation, policy and national defense are increasingly intertwined. Senator Young also weighs in on drug pricing, biotech investment and why strengthening the entire ecosystem from startups to large-scale manufacturers is essential for long-term leadership.

Listen to the full podcast on YouTube: https://www.youtube.com/watch?v=JZOpM8usxaI

04/29/2026

The Washington Post Opinions Editorial Board is calling it out. We need to reform the 340B program to restore accountability and ensure it actually delivers for patients.

A drug discount program has fueled consolidation and incentivized prescribing more expensive medications.

04/22/2026

A new piece from Bridge Michigan puts a human face on the debate around the federal 340B Drug Pricing Program. Originally designed to help safety-net healthcare providers manage resources and lower costs for vulnerable patients, the program is now under growing scrutiny for whether those savings are truly reaching the people it was intended to serve, not just for our neighbors in Michigan but across the country.

If it can happen to Garrina in Michigan, it's happening to patients here in Indiana, too.

Michigan needs to ensure no entity can misuse 340B, a program meant for patients. Michigan lawmakers have a chance to be leaders in this fight. They must reject proposals like House Bill 4878 that lack real accountability and guardrails.

04/20/2026

Small businesses don’t need more complexity in healthcare, they need clarity. That’s exactly what the new 340B Employer Cost Impact Calculator aims to provide.

By translating policy into dollars, the tool helps employers understand how much 340B may be adding to their health plan costs and here hidden financial pressures are coming from,

For small employers operating on tight margins, this kind of insight is critical.

By Karen Kerrigan – For small businesses, rising healthcare costs remain one of the most persistent and difficult challenges to manage. Premiums continue to climb, coverage becomes harder to sustain, and employers are left asking a simple question: What is actually driving these increases, and why...